5 Analysts Assess uniQure: What You Need To Know
During the last three months, 5 analysts shared their evaluations of uniQure (NASDAQ:QURE), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 1 | 1 | 0 | 0 |
| Last 30D | 0 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 1 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 2 | 1 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $45.4, a high estimate of $70.00, and a low estimate of $31.00. Observing a downward trend, the current average is 22.06% lower than the prior average price target of $58.25.
Decoding Analyst Ratings: A Detailed Look
The standing of uniQure among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Patrick R. Trucchio | HC Wainwright & Co. | Maintains | Buy | $70.00 | $70.00 |
| Eliana Merle | Barclays | Announces | Equal-Weight | $31.00 | - |
| Paul Matteis | Stifel | Lowers | Buy | $40.00 | $50.00 |
| Uy Ear | Mizuho | Lowers | Outperform | $33.00 | $60.00 |
| Daniil Gataulin | Chardan Capital | Maintains | Buy | $53.00 | $53.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to uniQure. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of uniQure compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of uniQure's stock. This comparison reveals trends in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into uniQure's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on uniQure analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Delving into uniQure's Background
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Unraveling the Financial Story of uniQure
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: uniQure's remarkable performance in 3M is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of 61.83%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: uniQure's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -2175.87%, the company may face hurdles in effective cost management.
Return on Equity (ROE): uniQure's ROE stands out, surpassing industry averages. With an impressive ROE of -71.66%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): uniQure's ROA stands out, surpassing industry averages. With an impressive ROA of -10.93%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: uniQure's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.29.
Analyst Ratings: Simplified
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.